Autolus Therapeutics (AUTL) Announces Proposed Public Offering in the United States
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/4/2026
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- HSBC stays aggressive on stocks, asks what could turn it bearish
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Crypto stocks sink as Bitcoin hits a 4-month low
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
Autolus Announces Proposed Public Offering in the United States
December 8, 2022 4:03 PM ESTLONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced an underwritten public offering of American Depositary Shares (ADSs), each ADS representing one ordinary share. All ADSs to be sold in the proposed offering will be offered by Autolus. Autolus also intends to grant the underwriters a 30-day option to purchase up to 15 percent of the ADSs sold in connection with the offering at the public offering price, on the same terms and conditions. The... More
Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
December 8, 2022 4:03 PM ESTDevelopment milestone of $35m achieved earlier than anticipated as a result of the positive interim analysis of Autolus pivotal FELIX Phase 2 trial, announced in a separate press release today
Manufacturing milestone of $35m achieved as a result of completion of planned activities supporting the performance and qualification of the obecabtagene autoleucel (obe-cel) manufacturing process
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that Blackstone... More
Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis
December 8, 2022 4:02 PM ESTObe-cel demonstrated Overall Remission Rate (ORR) of 70% in interim analysis of 50 patients with relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL)
Encouraging safety data observed, with 3% Grade 3 Cytokine Release Syndrome (CRS) and 8% Grade 3 Immune effector cell-associated neurotoxicity syndrome (ICANS) in 92 patients treated Achievement of development milestone has triggered payment of $35m from Blackstone Life Sciences, announced in a separate press release todayThe trial has completed screening patients for entry into the morphological cohort
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq:... More
